Featured Research

from universities, journals, and other organizations

Gender Matching Aids Long-term Survival After Heart Transplants

Date:
November 13, 2008
Source:
American Heart Association
Summary:
Men who received heart transplants from a male donor and women who had female donors had lower chances of death than patients who received a transplant from the opposite sex, according to a new 10-year study. Pairing female patients with male donors had the greatest risk for death during the study. Researchers said heart size and perhaps differences in the immune system explain the correlation.

Gender matching between donors and recipients is important to short- and long-term survival in heart transplantation, according to a retrospective study presented at the American Heart Association’s Scientific Sessions 2008.

“Heart size would seem to be the most obvious factor; beyond that, no one knows why sex matching is important to transplant survival,” said Eric Weiss, M.D., first author of the study and a post doctoral research fellow in the Division of Cardiac Surgery at The Johns Hopkins University Medical Institutions in Baltimore, Md. “In clinical transplantation, we generally don’t assume that organs from male and female donors have inherent differences affecting long-term outcomes, but our data suggest that there are important differences which must be taken into account.”

Researchers analyzed data from the United Network of Organ Sharing (UNOS), identifying 18,240 patients who received their first orthotopic (replacing a failing organ with a healthy one) heart transplant between 1998 and 2007. In this dataset, patients were followed for 10 years, with the average follow-up time being 3.4 years.

Patients were sorted into four groups: male donor with male recipient, female donor with male recipient, male donor with female recipient, and female donor with female recipient.

Overall, 71 percent were matched by gender to their donor (77 percent of male recipients and 51 percent of female recipients). Twenty-five percent of patients died during the study.

Matching donor and recipient by gender resulted in:

  • 13 percent lower risk of graft rejection within the first year;
  • 14 percent lower rate of graft rejection over the study period;
  • 25 percent drop in 30-day death rate; and
  • 20 percent lower one-year death rate.

Statistical modeling revealed that the greatest chance for death during the study occurred when pairing a male donor with a female recipient, which made the risk of death an estimated 20 percent higher compared to a male donor with male recipient. The most successful transplants occurred between male recipients and male donors, when the cumulative chance for survival was 61 percent.

“These results fit with our hypothesis that sex matching in heart transplantation leads to improved survival rates,” said Weiss, the Irene Piccinini Investigator in Cardiac Surgery. “We hypothesized that we would see a big difference in the short-term survival — which we did, most likely because of heart-size issues — but what was interesting was the substantial difference in the long term, as well.”

More than 2,000 transplant surgeries are done each year. Almost 87.5 percent of male recipients and 85.5 percent of female recipients live for more than a year after the transplant, according to American Heart Association statistics.

“We don’t recommend that patients wait longer for a same-sex organ,” Weiss said. “Clearly receiving a heart transplant from a donor of opposite sex is preferable to severe heart failure. If equivalent donors exist for a given patient, our data suggest that picking a sex matched donor may lead to improved short- and long-term survival.”

Co-authors are: Nishant D. Patel, B.A.; Stuart D. Russell, M.D.; William A. Baumgartner, M.D.; Ashish S. Shah, M.D.; and John V. Conte, M.D. Individual author disclosures can be found on the abstract.

A Health Resources and Services Administration contract and a Ruth L. Kirschstein National Research Service Award from the National Institutes of Health funded the study.


Story Source:

The above story is based on materials provided by American Heart Association. Note: Materials may be edited for content and length.


Cite This Page:

American Heart Association. "Gender Matching Aids Long-term Survival After Heart Transplants." ScienceDaily. ScienceDaily, 13 November 2008. <www.sciencedaily.com/releases/2008/11/081112113551.htm>.
American Heart Association. (2008, November 13). Gender Matching Aids Long-term Survival After Heart Transplants. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2008/11/081112113551.htm
American Heart Association. "Gender Matching Aids Long-term Survival After Heart Transplants." ScienceDaily. www.sciencedaily.com/releases/2008/11/081112113551.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins